RNA Avidity Biosciences

Filed: 17 Jun 21, 4:37pm





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 16, 2021




(Exact name of registrant as specified in its charter)




Delaware 001-39321 46-1336960

(State or other jurisdiction of

incorporation or organization)



File Number)


(I.R.S. Employer

Identification No.)

10975 N. Torrey Pines Road, Suite 150

La Jolla, California 92037

(Address of principal executive offices) (Zip Code)

(858) 401-7900

(Registrant’s telephone number, include area code)


(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, par value $0.0001 per share RNA The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.07.

Submission of Matters to a Vote of Security Holders.

Avidity Biosciences, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) on June 16, 2021. The following is a brief description of each matter voted upon at the 2021 Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.



The election of three nominees to serve as Class I directors for a three-year term to expire at the 2024 Annual Meeting of Stockholders. The following three Class I directors were elected by the votes indicated.


   For  Withheld  Broker Non-Votes

Carsten Boess

  28,420,872.74  2,757,358.03  2,380,939.00

Sarah Boyce

  28,038,877.74  3,139,353.03  2,380,939.00

Troy Wilson, Ph.D., J.D.

  22,802,272.74  8,375,958.03  2,380,939.00



The ratification of the appointment of BDO USA, LLP, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The appointment was ratified by the votes indicated:



 Against Abstain Broker Non-Votes
33,529,913.74 12,795.03 16,461.00 0.00


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



Date: June 17, 2021


/s/ Michael F. MacLean

   Name: Michael F. MacLean
   Title: Chief Financial Officer